Erratum: Modulation of p53 C-Terminal Acetylation by Mdm2, p14ARF, and Cytoplasmic SirT2 (Mol Cancer Ther (2013) 12 (471-180) DOI: 10.1158/1535-7163.MCT-12-0904);Modulation of p53 C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2

Molecular Cancer Therapeutics

Volumn 12, Issue 4, 2013, Pages 471-480

  Van Leeuwen, Ingeborg M M ^a   Higgins, Maureen ^b   Campbell, Johanna ^b   McCarthy, Anna R ^a   Sachweh, Marijke C C ^a   Navarro, Ana Marín ^a   Laín, Sonia ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; LYSINE; PROTEIN MDM2; PROTEIN P53; SIRTUIN 1; SIRTUIN 2;

ACETYLATION; ARTICLE; CATALYSIS; CHROMATIN; CYTOPLASM; DEACETYLATION; MODULATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN STABILITY; UBIQUITINATION;

EID: 84876459162     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-23-0759     Document Type: Erratum

References (54)

1. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137:609-22.
2. Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, et al. The C terminus of p53 binds the N-terminal domain of MDM2. Nat Struct Mol Biol 2010;17:982-9.
3. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A 2004;101:2259-64. (Pubitemid 38269299)
4. Brooks CL, Gu W. The impact of acetylation and deacetylation on the p53 pathway. Protein Cell 2011;2:456-62.
5. Martinez-Pastor B, Mostoslavsky R. Sirtuins, metabolism, and cancer. Front Pharmacol 2012;3:22.
6. Jin YH, Kim YJ, Kim DW, Baek KH, Kang BY, Yeo CY, et al. Sirt2 interacts with 14-3-3 beta/gamma and down-regulates the activity of p53. Biochem Biophys Res Commun 2008;368: 690-5.
7. Liu Y, Shevchenko A, Berk AJ. Adenovirus exploits the cellular aggre-some response to accelerate inactivation of the MRN complex. J Virol 2005;79:14004-16. (Pubitemid 41552699)
8. Li Y, Matsumori H, Nakayama Y, Osaki M, Kojima H, Kurimasa A, et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis. Genes Cells 2011;16:34-45.
9. Li S, Banck M, Mujtaba S, Zhou MM, Sugrue MM, Walsh MJ. p53-induced growth arrest is regulated by the mitochondrial SirT3 deace-tylase. PLoS ONE 2010;5:e10486.
10. Vakhrusheva O, Smolka C, Gajawada P, Kostin S, Boettger T, Kubin T, et al. Sirt7 increases stress resistance of cardiomyocytes and prevents apoptosis and inflammatory cardiomyopathy in mice. Circ Res 2008;102:703-10. (Pubitemid 351457857)
11. van Leeuwen I, Lain S. Sirtuins and p53. Adv Cancer Res 2009;102: 171-95.
12. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakeningguardian angels: drugging the p53 pathway. Nat Rev Cancer 2009;9:862-73.
13. Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237-45.
14. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997;420:25-7. (Pubitemid 28037193)
15. Kobet E, Zeng X, Zhu Y, Keller D, Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc Natl Acad Sci U S A 2000;97:12547-52.
16. Ito A, Lai CH, Zhao X, Saito S, Hamilton MH, Appella E, et al. p300/CBP-mediated p53 acetylation is commonly induced by p53-acti-vating agents and inhibited by MDM2. EMBO J 2001;20:1331-40. (Pubitemid 32233973)
17. Jin Y, Zeng SX, Dai MS, Yang XJ, Lu H. MDM2 inhibits PCAF (p300/CREB-binding protein-associated factor)-mediated p53 acetylation. J Biol Chem 2002;277:30838-43. (Pubitemid 34970783)
18. Ito A, Kawaguchi Y, Lai CH, Kovacs JJ, Higashimoto Y, Appella E, et al. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J 2002;21:6236-45. (Pubitemid 35415340)
19. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006;6:663-73. (Pubitemid 44285999)
20. Tao W, Levine AJ. Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci U S A 1999;96:3077-80. (Pubitemid 29148846)
21. Xirodimas D, Saville MK, Edling C, Lane DP, Lain S. Different effects of p14ARF on the levels of ubiquitinated p53 and Mdm2 in vivo. Onco-gene 2001;20:4972-83. (Pubitemid 32769787)
22. Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol 1999;1:20-6. (Pubitemid 129495005)
23. Llanos S, Clark PA, Rowe J, Peters G. Stabilization of p53 by p14ARF without relocation of MDM2 to the nucleolus. Nat Cell Biol 2001;3:445-52. (Pubitemid 32422079)
24. Rodway H, Llanos S, Rowe J, Peters G. Stability of nucleolar versus non-nucleolar forms of human p14(ARF). Oncogene 2004; 23:6186-92. (Pubitemid 39215288)
25. Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Coombes RC, et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 2010;9:844-55.
26. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010;24: 1580-9.
27. Clegg HV, Itahana Y, Itahana K, Ramalingam S, Zhang Y. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction. PLoS ONE 2012;7:e38212.
28. Blaydes JP, Hupp TR. DNA damage triggers DRB-resistant phos-phorylation of human p53 at the CK2 site. Oncogene 1998;17: 1045-52. (Pubitemid 28425415)
29. Lain S, Hollick JJ, Campbell J, Staples OD, Higgins M, Aoubala M, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008;13:454-63. (Pubitemid 351609441)
30. McCarthy AR, Pirrie L, Hollick JJ, Ronseaux S, Campbell J, Higgins M, et al. Synthesis and biological characterisation of sirtuin inhibitors based on the tenovins. Bioorg Med Chem 2012;20:1779-93.
31. McCarthy AR, Sachweh MCC, Higgins M, Campbell J, Drummond CJ, Van Leeuwen IMM, et al. Tenovin-D3, a novel small-molecule inhibitor of sirtuin SirT2, increases p21 expression in a p53-inde-pendent manner. Mol Cancer Ther 2013;12:352-60.
32. Bartkova J, Bartek J, Vojtesek B, Lukas J, Rejthar A, Kovarik J, et al. Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours. Eur J Cancer 1993;29A:881-6. (Pubitemid 23083623)
33. Midgley CA, Fisher CJ, Bartek J, Vojtesek B, Lane D, Barnes DM. Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci 1992;101:183-9.
34. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993;13:4107-14. (Pubitemid 23187639)
35. Midgley CA, Desterro JM, Saville MK, Howard S, Sparks A, Hay RT, et al. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiqui-tination in vitro and can activate p53 in vivo. Oncogene 2000;19:2312-23. (Pubitemid 30307207)
36. van Leeuwen IM, Higgins M, Campbell J, Brown CJ, McCarthy AR, Pirrie L, et al. Mechanism-specific signatures for small-molecule p53 activators. Cell Cycle 2011;10:1590-8.
37. Li M, Brooks CL, Wu-Baer F, Chen D, Baer R, Gu W. Mono-versus polyubiquitination: differential control of p53 fate by Mdm2. Science 2003;302:1972-5. (Pubitemid 37523506)
38. Xirodimas DP, Stephen CW, Lane DP. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp Cell Res 2001;270:66-77. (Pubitemid 32978090)
39. Carey MF, Peterson CL, Smale ST. Dignam and Roeder nuclear extract preparation. Cold Spring Harb Protoc 2009;2009:pdb prot5330.
40. Lain S, Midgley C, Sparks A, Lane EB, Lane DP. An inhibitor of nuclear export activates the p53 response and induces the localization of HDM2 and p53 to U1A-positive nuclear bodies associated with the PODs. Exp Cell Res 1999;248:457-72. (Pubitemid 29394805)
41. Li M, Chen D, Shiloh A, Luo J, Nikolaev AY, Qin J, et al. Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 2002;416:648-53. (Pubitemid 34406767)
42. Frye RA. Phylogenetic classification of prokaryotic and eukaryotic Sir2-like proteins. Biochem Biophys Res Commun 2000;273:793-8. (Pubitemid 30599063)
43. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990;10:6565-77. (Pubitemid 120004600)
44. North BJ, Verdin E. Interphase nucleo-cytoplasmic shuttling and localization of SIRT2 during mitosis. PLoS One 2007;2:e784.
45. Sekaric P, Shamanin VA, Luo J, Androphy EJ. hAda3 regulates p14ARF-induced p53 acetylation and senescence. Oncogene 2007;26:6261-8. (Pubitemid 47462111)
46. Hamard PJ, Manfredi JJ. Mdm2′s dilemma: to degrade or to translate p53?Cancer Cell 2012;21:3-5.
47. Brown DR, Thomas CA, Deb SP. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle-inhibitory function induces tumorigenesis. EMBO J 1998;17:2513-25. (Pubitemid 28221187)
48. Marshall GM, Liu PY, Gherardi S, Scarlett CJ, Bedalov A, Xu N, et al. SIRT1 promotes N-Myc oncogenesisthroughapositivefeedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet 2012;7:e1002135.
49. Li L, Wang L, Wang Z, Ho Y, McDonald T, Holyoake TL, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012;21:266-81.
50. Yuan H, Wang Z, Li L, Zhang H, Modi H, Horne D, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012;119:1904-14.
51. Vaseva AV, Marchenko ND, Ji K, Tsirka SE, Holzmann S, Moll UM. p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell 2012;149:1536-48.
52. Galluzzi L, Morselli E, Kepp O, Vitale I, Pinti M, Kroemer G. Mitochon-drial liaisons of p53. Antioxid Redox Signal 2011;15:1691-714.
53. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol 2010;22:181-5.
54. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. in vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303:844-8. (Pubitemid 38174664)